Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

J Comp Eff Res. 2018 Oct;7(10):947-958. doi: 10.2217/cer-2018-0020. Epub 2018 Aug 31.


Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111).

Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus.

Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS.

Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.

Keywords: MAIC; comparative effectiveness; everolimus; matching-adjusted indirect comparison; sunitinib.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Disease-Free Survival
  • Everolimus / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / mortality
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Progression-Free Survival
  • Proportional Hazards Models
  • Sunitinib / therapeutic use*
  • Treatment Outcome


  • Antineoplastic Agents
  • Everolimus
  • Sunitinib